2020 Packaging Pharmaceutical Manufacturing 
European Pharmaceutical Review
AUGUST 23, 2022
A study of the causes of warning letters issued by the US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) between 2010 and 2020 revealed that poor current good manufacturing practice (cGMP) compliance and misbranding were the most common citations.
European Pharmaceutical Review
JULY 25, 2022
Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. These may be mislabelled or produced in fake packaging and, most dangerously, there is no regulation around their manufacture. But what exactly does this look like? .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MAY 9, 2023
Whereas proper disposal of unused medications, as well as initiatives to reduce packaging waste, chemical waste, and improve recycling programmes, will aid in pro-actively addressing this challenge. This may involve the use of eco-friendly raw materials, green manufacturing processes, and eco-friendly packaging.
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Gene Ther 27, 537–544 (2020). Science 369, eabc3183 (2020).
Pharmaceutical Technology
NOVEMBER 21, 2022
However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).
Proxsys Rx
OCTOBER 6, 2022
That’s why helping health systems minimize data mismatches at the source is so critical to maximizing 340B savings 340B drug pricing program savings for a covered entity — and why meeting that challenge is a core component of our 340B software and service package.
Expert insights. Personalized for you.
105 
Let's personalize your content